Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions (Q38109960)

29 August 2017

0 references

Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions (English)

1 reference

29 August 2017

3

Michel Chrétien

1 reference

29 August 2017

Majambu Mbikay

1

1 reference

PubMed ID

23714205

29 August 2017

Janice Mayne

series ordinal

2

1 reference

29 August 2017

8 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

5

1 reference

29 August 2017

4

1 reference

29 August 2017

391-405

1 reference

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

29 August 2017

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

21 January 2018

The mystery of PCSK9.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

PCSK9: a promising therapeutic target for dyslipidemias?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Molecular biology of PCSK9: its role in LDL metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

PCSK9 and LDL cholesterol: unravelling the target to design the bullet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

PCSK9: an enigmatic protease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

PCSK9 function and physiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Recent patents on PCSK9: a new target for treating hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Clinical aspects of PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

PCSK9: an emerging target for treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Proprotein convertase subtilisin kexin9 (PCSK9): a novel target for cholesterol regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Anti-PCSK9 therapies for the treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

My road to Damascus: how I converted to the prohormone theory and the proprotein convertases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Moonlighting is mainstream: paradigm adjustment required

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Moonlighting proteins: old proteins learning new tricks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

The proprotein convertases, 20 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Biosynthesis and enzymatic characterization of human SKI-1/S1P and the processing of its inhibitory prosegment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Secreted site-1 protease cleaves peptides corresponding to luminal loop of sterol regulatory element-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Development of protein-based inhibitors of the proprotein of convertase SKI-1/S1P: processing of SREBP-2, ATF6, and a viral glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Impaired fertility in mice deficient for the testicular germ-cell protease PC4

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Proprotein convertase subtilisin/kexin type 4 in mammalian fertility: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Deletion of the gene encoding proprotein convertase 5/6 causes early embryonic lethality in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

A targeted deletion/insertion in the mouse Pcsk1 locus is associated with homozygous embryo preimplantation lethality, mutant allele preferential transmission and heterozygous female susceptibility to dietary fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Genetic deficiency for proprotein convertase subtilisin/kexin type 2 in mice is associated with decreased adiposity and protection from dietary fat-induced body weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

The proprotein convertases are potential targets in the treatment of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Increased stress-induced analgesia in mice lacking the proneuropeptide convertase PC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Automated design of ligands to polypharmacological profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Proprotein convertases furin and PC5: targeting atherosclerosis and restenosis at multiple levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 by the mammalian subtilisin/kexin-like convertases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Identification of a novel consensus sequence at the cleavage site of the Lassa virus glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

The proprotein convertase SKI-1/S1P. In vitro analysis of Lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Furin-induced cleavage and activation of Shiga toxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Inhibiting uterine PC6 blocks embryo implantation: an obligatory role for a proprotein convertase in fertility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Role of proprotein convertases in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Loss- and gain-of-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

In vivo evidence that furin from hepatocytes inactivates PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Functional characterization of Narc 1, a novel proteinase related to proteinase K

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Effects of the prosegment and pH on the activity of PCSK9: evidence for additional processing events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Utilizing HaloTag Technology to Track the Fate of PCSK9 from Intracellular vs. Extracellular Sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Annexin A2 at the interface of actin and membrane dynamics: a focus on its roles in endocytosis and cell polarization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Carboxypeptidase D is a potential candidate to carry out redundant processing functions of carboxypeptidase E based on comparative distribution studies in the rat central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Epithelial sodium channel/degenerin family of ion channels: a variety of functions for a shared structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Newly identified loci that influence lipid concentrations and risk of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Low density lipoprotein binding and uptake by human and rat islet beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Endocytosis of low-density lipoprotein by human pancreatic beta cells and uptake in lipid-storing vesicles, which increase with age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Adipose tissue remodeling and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

The biology and therapeutic targeting of the proprotein convertases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Adverse effects of statins - mechanisms and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Ethnic differences in the frequency of the cardioprotective C679X PCSK9 mutation in a West African population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Molecular population genetics of PCSK9: a signature of recent positive selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Of PCSK9, cholesterol homeostasis and parasitic infections: possible survival benefits of loss-of-function PCSK9 genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Metabolic fingerprints of serum, brain, and liver are distinct for mice with cerebral and noncerebral malaria: a ¹H NMR spectroscopy-based metabonomic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

PCSK9 as a therapeutic target of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

The Pore-forming Toxin Proaerolysin Is Activated by Furin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12064

21 January 2018

Identifiers

DOI

10.1111/1753-0407.12064

1 reference

29 August 2017

1 reference

PubMed ID

23714205